Suppr超能文献

对于患有 Diamond-Blackfan 贫血的年轻儿科患者,低强度预处理是造血干细胞移植有效的。

Reduced-intensity conditioning is effective for hematopoietic stem cell transplantation in young pediatric patients with Diamond-Blackfan anemia.

机构信息

Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Department of Hematology and Oncology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.

出版信息

Bone Marrow Transplant. 2021 May;56(5):1013-1020. doi: 10.1038/s41409-020-01056-1. Epub 2020 Sep 18.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for the hematologic manifestations of Diamond-Blackfan anemia (DBA). However, data regarding the optimal conditioning regimen for DBA patients are limited. We retrospectively compared the outcomes of DBA patients who underwent HSCT using either myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) regimens. The patients belonged to a cohort treated at our hospitals between 2000 and 2018. HSCT was performed in 27 of 165 patients (16.4%). The median age at the time of HSCT was 3.6 years. Stem cell sources included bone marrow for 25 patients (HLA-matched sibling donors, n = 5; HLA-mismatched related donors, n = 2; HLA-matched/mismatched unrelated donors, n = 18) or cord blood for 2 patients. MAC or RIC regimens were used in 12 and 15 patients, respectively. Engraftment was successful in all 27 patients who underwent HSCT. Three patients who underwent HSCT using MAC regimens developed sinusoidal obstruction syndrome. The 3-year overall survival (OS) and failure-free survival rates (FFS) post-transplantations were 95.2% and 88.4%, respectively, with no significant differences between MAC and RIC regimens. Our data suggest that HSCTs using RIC regimens are effective and obtain engraftment with excellent OS and FFS for young DBA patients.

摘要

异基因造血干细胞移植(HSCT)是治疗 Diamond-Blackfan 贫血(DBA)血液学表现的唯一根治性疗法。然而,关于 DBA 患者最佳预处理方案的数据有限。我们回顾性比较了接受清髓性预处理(MAC)或减低强度预处理(RIC)方案的 DBA 患者的 HSCT 结果。这些患者属于我们医院在 2000 年至 2018 年期间治疗的队列。在 165 例患者中,27 例(16.4%)接受了 HSCT。HSCT 时的中位年龄为 3.6 岁。干细胞来源包括骨髓 25 例(HLA 匹配的同胞供者 5 例;HLA 不匹配的亲缘供者 2 例;HLA 匹配/不匹配的无关供者 18 例)或脐带血 2 例。12 例患者采用 MAC 方案,15 例患者采用 RIC 方案。所有接受 HSCT 的 27 例患者均成功植入。3 例接受 MAC 方案预处理的患者发生肝窦阻塞综合征。移植后 3 年总生存率(OS)和无失败生存率(FFS)分别为 95.2%和 88.4%,MAC 和 RIC 方案之间无显著差异。我们的数据表明,RIC 方案的 HSCT 对年轻的 DBA 患者是有效且可获得植入,具有极好的 OS 和 FFS。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验